The U.S. Food and Drug Administration (FDA) has launched a new fast-track drug approval program that could cut review times to just 30 days, raising alarms from watchdogs who warn the program may sacrifice safety for speed.

Drug review times can now be cut "from 10-12 months to just 1-2 months," according to an agency press release.

The move comes after the U.S. House Committee on Energy and Commerce in October 2024 accused the FDA of "failing to meet safety requirements" and ignoring "important federal safety requirements to protect its employees and the public while also failing to prioritize scientific data quality."